“…In a DDS study, the therapeutic effects of the anticancer drug, 1,3-bis(2-chloroethyl)-1-nitrosourea, encapsulated into HLs composed of L-ɑ-dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene (20) sorbitan monolaurate (Tween 20) has been shown in an in vivo rat model of meningeal gliomatosis (Kitamura et al., 1996 ). In contrast, HLs composed of DMPC and polyoxyethylenedodecyl ether, without encapsulated anticancer drugs, was shown to inhibit the growth of various type of tumor cells and inducing apoptosis both in vitro (Matsumoto et al., 1999 , 2005 ; Iwamoto et al, 2005 ; Nagami et al., 2006 ; Komizu et al., 2011 ) and in vivo (Shimoda et al., 2009 ; Ichihara et al., 2012 , 2015 ). The therapeutic effects of HLs not containing encapsulated drugs, as an anticancer drug in patients with lymphoma has been reported (Ichihara et al., 2008 ).…”